Program Development Centre, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, The Netherlands.
Respir Med. 2012 Jun;106(6):871-4. doi: 10.1016/j.rmed.2012.01.008. Epub 2012 Feb 19.
Chronic obstructive pulmonary disease (COPD) is an increasing public health problem worldwide. Although epidemiologic data on COPD are important to raise awareness of the burden of disease, there are no actual spirometry-based data on the prevalence of COPD in the Netherlands.
Using the Burden of Obstructive Lung Disease (BOLD) protocol and study design, a population-based sample of adults, aged ≥ 40 years, in the area of Maastricht, the Netherlands was surveyed. Post-bronchodilator spirometry and questionnaires with information on smoking history and reported respiratory disease were collected. COPD was defined as post-bronchodilator FEV(1)/FVC ratio < 0,7 (GOLD) or < the lower limit of normal (LLN) (95th percentile) of the population distribution for FEV(1)/FVC. Data were statistically weighted for the total number of people in the Maastricht population.
Overall prevalence of COPD was 24%, and was higher for men (28.5%) than for women (195%). (unweighted p = 0.002) The prevalence of GOLD stage 2 or higher COPD was 10%. The prevalence of LLN-defined COPD was 19% and 10% for stage 2 or higher. Overall prevalence of current smoking was 23%. The prevalence of COPD increased with age and amount of pack-years, although 14% of never smokers fulfilled spirometric criteria for COPD. The prevalence of doctor-diagnosed COPD was only 8.8%.
Almost one quarter of the Maastricht population aged ≥ 40 years had COPD. Considering the ageing population and still an important smoking prevalence, this burden is bound to increase and imposes great demands to public health care and society in the Netherlands.
慢性阻塞性肺疾病（COPD）是全球日益严重的公共卫生问题。虽然 COPD 的流行病学数据对于提高对疾病负担的认识很重要，但荷兰尚无实际基于肺量计的 COPD 患病率数据。
使用负担性阻塞性肺病（BOLD）方案和研究设计，对荷兰马斯特里赫特地区年龄≥40 岁的成年人进行了一项基于人群的抽样调查。进行支气管扩张剂后肺量测定，并收集了有关吸烟史和报告的呼吸道疾病的问卷。COPD 定义为支气管扩张剂后 1 秒用力呼气量（FEV1）/用力肺活量（FVC）<0.7（GOLD）或<FEV1/FVC 的人群分布的下限（LLN）（95%百分位数）。对马斯特里赫特人群的总人数进行了数据统计加权。
COPD 的总体患病率为 24%，男性（28.5%）高于女性（19.5%）（未加权，p=0.002）。GOLD 2 期或更高级别的 COPD 患病率为 10%。LLN 定义的 COPD 患病率为 19%，2 期或更高级别的患病率为 10%。当前吸烟的总体患病率为 23%。COPD 的患病率随年龄和吸烟包年数的增加而增加，尽管 14%的从不吸烟者符合 COPD 的肺量计标准。医生诊断的 COPD 患病率仅为 8.8%。
马斯特里赫特地区≥40 岁的人群中，近四分之一患有 COPD。考虑到人口老龄化和仍然很高的吸烟率，这种负担必然会增加，并对荷兰的公共卫生保健和社会造成巨大需求。
